Polatuzumab Vedotin Combined with R-ICE (PolaR-ICE) As Second-Line Therapy in Relapsed/Refractory Diffuse Large B-Cell LymphomaAlex F. Herrera, Matthew J. Matasar, Steven T. Rosen et al.|Blood|2022Cited by 18
Real-World (RW) Outcomes of Lisocabtagene Maraleucel (liso-cel) As Second-Line (2L) Therapy in Patients (pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): First Results from the Center for International Blood and Marrow Transplant Research (CIBMTR) RegistryMaría Silvina Odstrcil Bobillo, Matthew J. Frigault, Swetha Kambhampati et al.|Blood|2024Cited by 7
Real-world outcomes of frontline polatuzumab-rchp and impact of frailty in older adults with diffuse large B-cell lymphomaVarun Iyengar, Pallawi Torka, Jomel Meeko Manzano et al.|Blood|2025Cited by 1
Outcomes of CD20xCD3 bispecific antibody therapy in adult patients with Relapsed/Refractory transformed indolent lymphomaPierre Stéphan, Jennifer L. Crombie, Karan Chohan et al.|Blood|2025Cited by 0
Sequencing CD20-directed bispecific antibody and CD19-directed CAR T cell therapy in large B cell lymphoma: A multicenter real-world studyDavid Qualls, Sairah Ahmed, Andrew Jallouk et al.|Blood|2025Cited by 0